AI Outperforms Biopsy in Assessing Rare Cancers, Study Reveals

Artificial intelligence (AI) has shown to be nearly twice as accurate as biopsies in assessing the aggressiveness of rare types of cancer, according to a study by researchers from the Royal Marsden NHS Foundation Trust and the Institute for Cancer Research. The AI algorithm, trained on CT scans of patients with retroperitoneal sarcoma, accurately assessed tumor aggressiveness 82% of the time, compared to 44% for biopsies. The technology also predicted the type of sarcoma in 84% of cases, compared to 65% for radiologists. The researchers believe this approach could improve diagnosis, treatment planning, and outcomes for patients with retroperitoneal sarcoma and potentially other types of cancer.